If you or a loved one has been diagnosed with Alzheimer's disease, or a physician suspects it may be Alzheimer's disease, you or they may be eligible to participate in a clinical research study to help advance the treatment of Alzheimer’s.
You or a loved one may qualify for a clinical study for individuals experiencing symptoms of Alzheimer's disease. You may qualify for the study, if:
If you are between the ages of 50 and 87,...
have been recently diagnosed or have a suspected clinical diagnosis of Alzheimer's disease,...
and have been vaccinated for COVID-19 or have had a previous COVID-19 infection.*
* Other criteria may apply.
The rethinkALZ and refocusALZ clinical research studies are currently enrolling patients. The purpose of these research studies is to learn more about the use of the study drug, simufilam, for the treatment of mild-to-moderate Alzheimer's disease. We want to test that it is safe and find out whether it can slow down disease progression and improve thinking and memory in people with Alzheimer’s disease.
To be considered for the rethinkALZ or refocusALZ study, patients must:
To be considered please click on the button below and fill the form.
Advanced Research Center, Inc. (ARC) is a clinical research site dedicated to administering Phase 2, 3, and 4 clinical trials. We have over 16 years of experience conducting clinical trials across various therapeutic areas, emphasizing Internal Medicine, Pediatrics, and Psychiatry/Central Nervous System.